What is Wedbush’s Forecast for ZNTL FY2024 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at Wedbush boosted their FY2024 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, January 29th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($2.25) per share for the year, up from their prior forecast of ($2.33). Wedbush currently has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.58) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.97) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($0.63) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Several other equities research analysts also recently issued reports on the stock. UBS Group cut their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. HC Wainwright cut their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL opened at $1.63 on Monday. The stock has a market capitalization of $116.16 million, a PE ratio of -0.65 and a beta of 1.86. Zentalis Pharmaceuticals has a 52 week low of $1.61 and a 52 week high of $18.07. The stock has a 50 day moving average price of $2.87 and a 200 day moving average price of $3.23.

Insider Transactions at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Jan Skvarka bought 60,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Ieq Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $46,000. Savant Capital LLC acquired a new position in Zentalis Pharmaceuticals during the 4th quarter worth approximately $72,000. SG Americas Securities LLC boosted its holdings in Zentalis Pharmaceuticals by 115.6% in the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after acquiring an additional 30,240 shares in the last quarter. Barclays PLC grew its stake in Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after acquiring an additional 11,748 shares during the period. Finally, XTX Topco Ltd increased its holdings in shares of Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after acquiring an additional 15,597 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.